The company’s in-house KRAS G12C inhibitorKRAS G12C inhibitor received the designation from the Center for Drug Evaluation of China’s National Medical Products Administration.
Recommended Reports
Preview
Source: Pharmaceutical Technology
ReportsInnovation in Pharmaceuticals: Cyclosporin derivatives GlobalData
Preview
Source: Pharmaceutical Technology
ReportsInnovation in Pharmaceuticals: Periodontitis drugs GlobalData
View all
The BTD has been granted based on the results from an ongoing pivotal, multi-centre, single-arm, open-label study that assessed the safety and efficacy of the single agent glecirasib.
Jacobio is also currently conducting a pivotal Phase I/II monotherapy study in China evaluating glecirasib in STK11 [a germline mutation] co-mutated NSCLC patients in the front-line setting.
Other Phase I/II clinical trials of glecirasib are ongoing in Europe and the US for treating patients with advanced solid tumours harbouring the KRAS G12C mutation.
The company also develops new molecules that target immune checkpoints, tumour metabolism and P53, RB and MYC-signalling pathways.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.